DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jmjl38/renal) has announced the addition of the "Renal Stones/Calculi Global Clinical Trials Review, H1, 2015" report to their offering.
Renal Stones/Calculi Global Clinical Trials Review, H1, 2015" provides data on the Renal Stones/Calculi clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Renal Stones/Calculi. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Renal Stones/Calculi.
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Top Companies Participating in Renal Stones/Calculi Therapeutics Clinical Trials
- Astellas Pharma Inc.
- The Himalaya Drug Company
- Omeros Corporation
- Allena Pharmaceuticals, Inc.
- Indus Biotech Private Limited
- Hamad Medical Corporation
- Catalysis, S.L.
- Actavis plc
For more information visit http://www.researchandmarkets.com/research/jmjl38/renal
